Immuneering (IMRX) Operating Expenses (2020 - 2026)

On a trailing twelve-month basis, Immuneering's Operating Expenses was $63.47 million through Jun 30, 2026, down 0.9% year-over-year; for FY2025, it came in at $59.38 million, down 7.3% from FY2024.

• Operating Expenses shows a five-year compound annual growth rate of 26.8% (FY2020 to FY2025).
• In earlier years, Operating Expenses was $64.07 million in FY2024 (+9.7%), $58.41 million in FY2023 (+12.5%), $51.9 million in FY2022 (+49.1%) and $34.81 million in FY2021 (+92.2%).
• The Q2 2026 figure marks the highest quarterly Operating Expenses in data going back to Q2 2020.
• Compared with a year earlier, Operating Expenses was higher in five of the last eight quarters, with growth averaging 3.3%.
• The best year-over-year quarter for Operating Expenses over five years was Q1 2022 (growth of 98.0%); the worst was Q4 2025 (a decline of 25.9%).
• Per Business Quant data, IMRX's Operating Expenses in the three quarters before Q2 2026 was $15.34 million (Q1 2026), $13.75 million (Q4 2025) and $15.38 million (Q3 2025).